Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Treatment Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Female Patients and Comparison of the Efficacy with That of Male Patients

NCT06509139 is registered in ClinicalTrials.gov with National Cheng-Kung University Hospital as lead sponsor.

NCT NCT06509139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06509139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Treatment Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Female Patients and Comparison of the Efficacy with That of Male Patients
Lead sponsor
National Cheng-Kung University Hospital
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
July 9, 2024
Completion date
July 31, 2032
Enrollment
661 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bismuth quadruple therapy, helicobacter pylori infection, sex